Rafik Fellague-Chebra, Executive Global Group medical Director of Novartis Oncology, shared a post on LinkedIn:
“The hidden synergies between gut pathobionts in colorectal cancer
In this recent study researchers reveal a fascinating interaction between the gut pathogen Candida albicans and the oral anaerobe Fusobacterium nucleatum, and how this interaction drives colorectal cancer progression. By uncovering the molecular mechanisms behind this cross-kingdom synergy via the Flo9-RadD axis, we have opened up new options for targeted interventions in oncology.
These findings challenge the prevailing view of the microbiome as a static entity in cancer and demonstrate its dynamic, interactive role in shaping the tumor landscape. Importantly, it shows that Candida and Fusobacterium not only co-exist, but actively collaborate to promote cancer growth and invasiveness – a collaboration that appears to be mediated by a specific protein-protein interaction.
These insights have profound implications for colorectal cancer diagnosis, prognosis, and treatment. By mapping the microbiome signatures associated with high-risk disease, we can now envision novel strategies for early detection and patient stratification. Furthermore, targeting the Flo9-RadD axis or modulating the gut-oral microbial axis could emerge as promising therapeutic avenues to disrupt this insidious partnership and improve clinical outcomes.”
Title: Candida albicans synergizes with Fusobacteriumnucleatum in colorectal cancer progression via the Flo9-RadD interaction
Authors: Jialu Li, Chenyi Zhang, Xinhua Huang, Hongxiang Sun, Lei Yang, Hongzhi Liu, Lu Zhang, Ningbo Wu, Yuanhong Xie, Jingjing Qi, Xiaoxu Leng, Yun Cui, Song Li, Ziran Kang, Zhuolei Kou, Ning-Ning Liu, Pengfei Lan, Beilei Xuan, Dengfeng Cao, Guo-Xiang Cai, Yingxuan Chen, Jianfeng Chen, Zhaoyuan Liu, Florent Ginhoux, Changbin Chen, Bing Su, Jing-Yuan Fang
Read the full article.
